SubHero Banner
Text

Lumakras(sotorasib) – New orphan drug approval

May 28, 2021- The FDA announced the approval of Amgen’s Lumakras (sotorasib), for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

Download PDF